CD19-BCMA CAR-T
/ Air Force Medical University
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 16, 2025
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Ting Chang, MD | Trial primary completion date: Mar 2025 ➔ Nov 2025
Trial primary completion date • CNS Disorders • Myasthenia Gravis
1 to 1
Of
1
Go to page
1